Veracyte, Inc. · NASDAQ:VCYT
Veracyte — Investor Presentation (June 2026)
20 slides from Veracyte's investor presentation, Jun 1, 2026
Slide 1: Investor Call on ASCO Findings
Investor Call on ASCO Findings June 1, 2026 © 2026 Veracyte, Inc. All rights reserved. 1
Slide 2: Forward-looking statements
Forward -looking statements This presentation contains forward -looking statements, including, but not limited to our statements related to our plans, object ives, and expectations (financial and otherwise), including with respect to the timeline for commercial availability of our MRD platform and i
Slide 3: Practice-changing evidence demonstrating how our tests can guide treatment decisions
Practice -changing evidence demonstrating how our tests can guide treatment decisions Predictive evidence in Predictive evidence in early-stage breast cancer metastatic prostate cancer OPTIMA ENZAMET Abstract title: “ First results from the OPTIMA phase Abstract title: “ Assessment of the ability of
Slide 4: Today's participants
Today’s participants Marc Stapley Chief Executive Officer, Veracyte Iain Macpherson, Ph.D. Principal Investigator of OPTIMA Professor of Breast Oncology at the University of Glasgow John Leite, Ph.D. Chief Commercial Officer, Veracyte Phil Febbo, M.D. Chief Scientific Officer & Chief Medical Officer
Slide 5: OPTIMA Prelim supported the selection of the Prosigna test for the Phase III OPTIMA trial
OPTIMA Prelim supported the selection of the Prosigna test for the Phase III OPTIMA trial OPTIMA Prelim served as a head -to -head comparison evaluating the performance of the Prosigna test and other genomic tests in patients with high -risk breast cancer. The Prosigna test had higher prognostic acc
Slide 6: OPTIMA design
OPTIMA design Main eligibility criteria • Nodes: ▸0-9N+, • Women & men age ≥40 with excised breast cancer ▸minimum T-size requirement if N0/ N1mi • ER-pos (IHC>10%) & HER2-neg • Neoadjuvant chemotherapy prohibited Prosigna* Control arm chemo. endocrine informed 1 blinded to randomisation consent R 1
Slide 7: Statistical design
Statistical design Primary outcome: Invasive Breast Cancer Free Survival (IBCFS) endpoint Local / regional / distant relapse; second primary breast cancer; death from any cause Does not include new, non -breast cancers Primary analysis: per -protocol population – minimum follow -up of one year Non -
Slide 8: Invasive Breast Cancer Free Survival
8 Invasive Breast Cancer Free Survival Complete Per Protocol population ROR ≤60 subpopulation 100 100 Invasive breast cancer free survival (%) Invasive breast cancer free survival (%) 75 75 Adjusted HR 1.06; 90% CI 0.80-1.40, Adjusted HR 1.03; 90% CI 0.85-1.25, 50 p(3.5%noninferiority) = 0.003 50 p(
Slide 9: Subgroup analysis: low ROR score population
Subgroup analysis: low ROR score population 9 PRESENTED BY:
Slide 10: IBCFS vs menopausal status: low ROR score population
10 IBCFS vs menopausal status: low ROR score population Premenopausal Postmenopausal 100 100 Invasive breast cancer free survival (%) Invasive breast cancer free survival (%) 75 75 HR 1.04; 95% CI 0.60-1.80 HR 1.14; 95% CI 0.76-1.71 50 50 No. %IBCFS (95% CI) No. %IBCFS (95% CI) events at 5 years eve
Slide 11: IBCFS vs nodal status: low ROR score population
11 IBCFS vs nodal status: low ROR score population 1-3 involved nodes 4-9 involved nodes 100 100 Invasive breast cancer free survival (%) Invasive breast cancer free survival (%) 75 75 HR 1.11; 95% CI 0.76-1.64 HR 1.19; 95% CI 0.62-2.29 50 50 No. %IBCFS (95% CI) No. %IBCFS (95% CI) events at 5 years
Slide 12: IBCFS vs stage prognostic groups: low ROR score population
12 IBCFS vs stage prognostic groups: low ROR score population PRESENTED BY:
Slide 13: Conclusions
Conclusions Chemotherapy can be safely avoided for many patients The Prosigna test identified that more than two thirds of high -risk node -positive patients, who previously would have received chemotherapy, could safely forgo it entirely without compromising outcomes or increasing recurrence risk.
Slide 14: Prosigna will uniquely benefit from insights learned from the OPTIMA trial
Prosigna will uniquely benefit from insights learned from the OPTIMA trial due to discordant results with other tests TransATAC Study © 2026 Veracyte, Inc. All rights reserved. 14 Richard Buus et al.; Molecular Drivers of Oncotype DX, Prosigna , EndoPredict , and the Breast Cancer Index: A TransATAC
Slide 15: OPTIMA supports Prosigna-directed chemotherapy decisions in broadest high-risk population to-date
OPTIMA supports Prosigna -directed chemotherapy decisions in broadest high -risk population to -date ~225,000 patients diagnosed annually 1 Post -menopausal Pre -menopausal with early -stage hormone receptor positive disease and women women all are eligible and appropriate for Prosigna testing The P
Slide 16: Clinical evidence supporting the Prosigna test is extensive and growing
Clinical evidence supporting the Prosigna test is extensive and growing Legend: Ongoing In Analysis Published OPTIMA Development Clinical Prognostic 1 Clinical Predictive 2 Real -World / Decision -Impact GEP Test Comparisons 1. Demonstrates that PAM50 or the Prosigna test can predict recurrence. 16
Slide 17: ENZAMET study provides Level 1B evidence for Decipher in metastatic prostate cancer
ENZAMET study provides Level 1B evidence for Decipher in metastatic prostate cancer International, randomized Phase III study Pre -specified biomarker analysis using the conducted by the Australian and New Zealand Decipher Prostate test in 634 patients with Urogenital and Prostate Trials Group (ANZU
Slide 18: ENZAMET study expands the Decipher evidence base for high-risk and metastatic prostate cancer
Of the ~334K 1 patients ENZAMET study expands the diagnosed with prostate cancer each year, Decipher evidence base for ~30K 2 patients have metastatic disease high -risk and metastatic prostate cancer into triplet therapy STAMPEDE & CHAARTED ENZAMET Decipher Prostate is validated across the full Pre
Slide 19: A novel platform for growth
A novel platform for growth Veracyte Diagnostics Platform Broad genomic assays, expansive clinical data, and robust evidence generation 19
Slide 20: Veracyte
Wveracyte.